Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast

Figures & data

Figure 1 Chemical structures of approved triphenylethylene SERMs, (selective estrogen receptor modulator) ie, tamoxifen, toremifene, and ospemifene.

Figure 2 Chemical structures of known steroidal estrogens found in the clinical formulation of conjugated equine estrogens.

Table 1 Incidence of more common (≥1%) and rare side effects seen with ospemifene (60 mg) treatment compared with placebo

Side effect	Incidence (%)
	Ospemifene 60 mg (n = 1,242)	Placebo (n = 958)
Hot flashes	7.5	2.6
Vaginal discharge	3.8	0.3
Genital discharge	1.3	0.1
Muscle spasms	3.2	0.9
Hyperhidrosis	1.6	0.6
Stroke
Hemorrhagic	0.145	0
Thromboembolic	0.072	0.104
Deep vein thrombosis	0.145	0.104

Note: Data from Osphena™ (ospemifene) prescribing information.⁴⁴

Osphena™ (ospemifene) prescribing informationFlorham Park, NJShionogi Inc2013 Available from: http://www.shionogi.com/pdf/PI/Osphena-PI.pdfAccessed August 22, 2013

 Google Scholar